Clinical trial

A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy

NCT03270176

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2017-10-10

PhasePHASE1

Study timeline

Study start (actual)2017-10-10Date precision: day

Registry last updated2022-06-01

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Carcinoma, Non-Small-Cell Lungunresolved

Neoplasmsunresolved

Interventions

Debio 1143DRUG

AvelumabDRUG · verified · RxNorm: avelumab

Sponsors & collaborators

Debiopharm International SAlead sponsor

Mapped research locations

VancouverBritish Columbia, Canada1 OttawaOntario, Canada1 EdmontonAlberta, Canada1 HamiltonOntario, Canada1 PoznanPoland1 LodzPoland1 Cluj-NapocaRomania1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03270176 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.